Solution structure of acidic fibroblast growth factor bound to 1,3,6-naphthalenetrisulfonate: A minimal model for the anti-tumoral action of suramins and suradistas

Journal of Molecular Biology

Volumn 281, Issue 5, 1998, Pages 899-915

  Lozano, Rosa M ^a   Jiménez, M Ángeles ^b   Santoro, Jorge ^b   Rico, Manuel ^b   Giménez Gallego, Guillermo ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b INSTITUTO DE ESTRUCTURA DE LA MATERIA   (Spain)

Author keywords

Angiogenesis inhibitors; Anti angiogenic tumour therapy; Fibroblast growth factors; Suradistas; Suramin

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; HEPARIN; NAPHTHALENESULFONIC ACID DERIVATIVE; SURADISTA; SURAMIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; MITOGENESIS; PRIORITY JOURNAL; PROTEIN STRUCTURE;

EID: 0032483474     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1998.1977     Document Type: Article

References (71)

1. Aue W.P., Bartholdi E., Ernst R.R. Two-dimensional spectroscopy. Application to nuclear magnetic resonance. J. Chem. Phys. 64:1976;2229-2246
2. Baird A., Böhlen P. Fibroblast growth factors. Sporn M.B., Roberts A.B. Handbook of Experimental Pharmacology, "Peptide Growth Factors and Their Receptors" vol. 95:1990;369-418 Springer, Berlin
3. Bax A., Davies D. Practical aspects of two-dimensional transverse NOE spectroscopy. J. Magn. Reson. 65:1985;355-360
4. Biasoli G., Botta M., Ciomei M., Corelli F., Grandi M., Manetti F., Mongelli N., Paio A. New heterocyclic analogs of suramin with bFGF inhibiting activity. Synthesis, SAR and possible mode of action. Med. Chem. Res. 4:1993;202-210
5. Braddock P.S., Hu D.-E., Fan T.-P.D., Stratford I.J., Harris A.L., Bicknell R. A structure-activity analysis of antagonism of the growthfactor and angiogenic activity of basic fibroblast growth factorby suramin and related polyanions. Brit. J. Cancer. 69:1994;890-898
6. Burgess W.H., Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu. Rev. Biochem. 58:1989;575-606
7. Ciomei M., Pastori W., Mariani M., Sola F., Grandi M., Mongelli N. New sulfonated distamycin A derivatives with bFGF complexing ativity. Biochem. Pharmacol. 47:1994;295-302
8. The CCP4 suite programs for protein crystallography. Acta Crystallog. sect. D. 50:1994;760-763
9. Copeland R.A., Hanlee J., Halfpenny A.J., Williams R.W., Thomson K.C., Herber W.K., Thomas K.A., Bruner M.W., Ryan J.A., Marquis-Omer D., Sanyal G., Sitren R.D., Yamazaki S., Middaugh R. The structure of human acidic fibroblast growth factor and its interaction with heparin. Arch. Biochem. Biophys. 289:1991;53-61
10. Coulier F., Pontarotti P., Roubin R., Hartung H., Goldfarb M., Birnbaum D. Of worms and men an evolutionary perspective on the fibroblast growth factor (FGF) and FGF receptor families. J. Mol. Evol. 44:1997;43-56
11. Ellis L.M., Fidler I.J. Angiogenesis and metastasis. Eur. J. Cancer. 32A:1996;2451-2460
12. Esch F., Baird A., Ling N., Ueno N., Hill F., Denoroy L., Klepper R., Gospodarowicz D., Bohlen P., Guillemin R. Primary structure of bovine pituitary fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine acidic FGF. Proc. Natl Acad. Sci. USA. 82:1985;6507-6511
13. Faham S., Hileman R.E., Fromm J.R., Linhardt R.J., Rees D.C. Heparin structure and interactions with basic fibroblast growth factor. Science. 271:1996;1116-1120
14. Folkman J. Tumor angiogenesis therapeutic implications. New Engl. J. Med. 285:1971;1182-1186
15. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1:1995;27-31
16. Folkman J., Klagsbrun M. Angiogenic factors. Science. 235:1987;442-447
17. Fontana A., Fassina G., Vita C., Dalzoppo D., Moreno Z., Zambonin M. Correlation between sites of limited proteolysis and segmental mobility in thermolysin. Biochemistry. 25:1986;1847-1851
18. Fromm J.R., Hileman R.E., Weiler J.M., Linhardt R.J. Interaction of fibroblast growth factor-1 and related peptides with heparan sulfate and its oligosaccharides. Arch. Biochem. Biophys. 346:1997;252-262
19. Gagliardi A., Hadd H., Collins D.C. Inhibition of angiogenesis by suramin. Cancer Res. 52:1992;5073-5075
20. Gagliardi A., Kassack M., Kreimeyer A., Muller G., Nickel P., Collins D.C. Antiangiogenic and antiproliferative activity of suramin analogues. Cancer Chemoter. Pharmacol. 41:1998;117-124
21. Gasparini G., Harris A.L. Clinical importance of the determination of tumor angiogenesis in breast carcinoma much more than a new prognostic tool. J. Clin. Oncol. 13:1995;765-782
22. Giménez-Gallego G., Cuevas P. Fibroblast growth factor, a protein with a broad spectrum of biological activities. Neurolog. Res. 16:1994;313-316
23. Giménez-Gallego G., Con G., Hatcher V.B., Thomas K.A. Human brain-derived acidic and basic fibroblast growth factors amino terminal sequences and specific mitogenic activities. Biochem. Biophys. Res. Commun. 135:1986;541-548
24. Güntert P., Wüthrich K. Improved efficiency of protein structure calculations from NMR data using the program DIANA with redundant dihedral angle constraints. J. Biomol. NMR. 1:1991;447-456
25. Güntert P., Braun W., Wüthrich K. Efficient computation of the three-dimensional protein structures from NMR using the program DIANA and the supporting programs CALIBA, HABAS and GLOMSA. J. Mol. Biol. 217:1991;517-530
26. Hajduk P.J., Meadows R.P., Fesik S.W. Discovering high affinity ligands for proteins. Science. 278:1997;497-499
27. Hayek A., Culler F.L., Beattie G.M., López A.D., Cuevas P., Baird A. An in vivo model for study of the angiogenic effects of basic fibroblast growth factor. Biochem. Biophys. Res. Commun. 147:1987;876-880
28. Hori A., Sasada R., Matsutani E., Naito K., Sakura Y., Fujita T., Kozai Y. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody aganist human basic fibroblast growth factor. Cancer Res. 51:1991;6180-6184
29. Jaye M., Schlessinger J., Dionne C.A. Fibroblast growth factor receptor tyrosine kinases molecular analysis and signal transduction. Biochim. Biophys. Acta. 1135:1992;185-199
30. Jonca F., Ortega N., Gleizes P.E., Bertrand N., Plouet J. Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor. J. Biol. Chem. 272:1997;24203-24209
31. Kleywegt G., Jones A. Detection, delineation, measurement ad display of cavities in macromolecular structures. Acta Crystallog. sect. D. 50:1994;178-185
32. Kumar A., Ernst R.R., Wüthrich K. A two-dimensional nuclear Overhauser enhancement (2D NOE) experiment for the elucidation of complete proton-proton cross-relaxation networks in biological macromolecules. Biochem. Biophys. Res. Commun. 95:1980;1-6
33. Lozano R.M., Rivas G., Giménez-Gallego G. Destabilization, oligomerization and inhibition of the mitogenic activity of acidic fibroblast growth factor by aurintricarboxylic acid. Eur. J. Biochem. 248:1997;30-36
34. Mandriota S.J., Pepper M.S. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J. Cell Sci. 110:1997;2293-2302
35. Mariani M., Paio A., Ciomei M., Pastori W., Franzetti C., Melegaro G., Grandi M., Mongelli N. In vitro activity of the novel sulfonic derivatives of distamycin A. Experient. Suppl. 61:1992;455-458
36. Marion D., Wüthrich K. Application of phase-sensitive two-dimensional correlated spectroscopy (COSY) for measurement of proton-proton spin-spin coupling constants. Biochem. Biophys. Res. Commun. 113:1983;967-974
37. Middaugh C.R., Mach H., Burke C.J., Volkin D.B., Dabora J.M., Tsai P.K., Bruner M.W., Ryan J.A., Marfia K.E. Nature of the interaction of growth factors with suramin. Biochemistry. 31:1992;9016-9024
38. Morris A.D., Leonce S., Guilbaud N., Tucker C.G., Perez V., Jan M., Cordi A.A., Pierre A., Atassi G. Eriochrome Black T, structurally related to suramin, inhibits angiogenesis and tumor growth in vivo. Anti-Cancer Drugs. 8:1997;746-755
39. Murzin A.G., Lesk A.M., Chothia C. β-Trefoil fold. Patters of structure and sequence in the Kunitz inhibitors, interleukins-1β and 1α and fibroblast growth factors. J. Mol. Biol. 233:1992;531-543
40. Myers C., Cooper M., Stein C., LaRoca R., Walther M., Weiss G., Choyke P., Dawson N., Steinberg S., Uhrich M., Cassidy J., Kohler K., Trepel J., Lunehan W. Suramin a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 10:1992;881-889
41. Ornitz D.M., Yayon A., Flanagan J.G., Svahn C.M., Levi E., Leder P. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol. Cell. Biol. 12:1992;240-247
42. Pantoliano M.W., Horlick R.A., Springer B.A., Van Dyk D.E., Tobery T., Wetmore D.R., Lear J.D., Nahapetian A.T., Bradley J.D., Sisk W.P. Multivalent ligand-receptor binding interactions in the fibroblast growth factor system produce a cooperative growth factor and heparin mechanism for receptor dimerization. Biochemistry. 33:1994;10229-10248
43. Pesenti E., Sola F., Mongelli N., Grandi M., Spreafico F. Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. Brit. J. Cancer. 66:1992;367-372
44. Pineda-Lucena A., Nuñ I., Lozano R.M., Muñ I., Zazo M., Giménez-Gallego G. Effect of low pH and heparin on the structure of acidic fibroblast growth factor. Eur. J. Biochem. 222:1994;425-431
45. 1H-NMR assignment and solution structure of human acidic fibroblast growth factor activated by inositol hexasulfate. J. Mol. Biol. 242:1994;81-98
46. Pineda-Lucena A., Jiménez M.A., Lozano R.M., Nieto J.L., Santoro J., Rico M., Giménez-Gallego G. Three-dimensional structure of the acidic fibroblast growth factor in solution effects of binding to a heparin funcional analogue. J. Mol. Biol. 264:1996;162-178
47. Pinedo H., van Rijswijk R. Suramin awakes? J. Clin Oncol. 10:1992;875-877
48. Piotto M., Saudek V., Sklenar V. Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions. J. Biomol. NMR. 6:1992;661-665
49. Polverino de Laureto P., De Filippis V., Di Bello M., Zambonin M., Fontana A. Probing the molten globule state of α-lactalbumin by limited proteolysis. Biochemistry. 34:1995;12596-12604
50. Rapraeger A.C., Krufka A., Olwin B.B. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science. 252:1991;1705-1708
51. Relf M., LeJeune S., Scott P.A.E., Fox S., Smith K., Leek R., Moghaddam A., Whitehouse R., Bicknell R., Harris A.L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotropin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57:1997;963-969
52. Roghani M., Mansukhani A., Dell'Era P., Bellosta P., Basilico C., Rifkin D.B., Moscatelli D. Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding. J. Biol. Chem. 269:1994;3976-3984
53. Romero A., Pineda-Lucena A., Giménez-Gallego G. X-ray analysis structure of native full length human fibroblast growth factor at 0.25 nm resolution. Eur. J. Biochem. 241:1996;453-461
54. Rosengart T.K., Kuperschmid J.P., Maciag T., Clark R. Parmacokinetics and distribution of heparin-binding growth factor I (endothelial cell growth factor) in the rat. Circ. Res. 64:1989;227-234
55. Saclarides T.J. Angiogenesis in colorectal cancer. Surg. Clin. North America. 77:1997;253-260
56. Signor G., Vita C., Fontana A., Frigerio F., Bolognesi M., Toma S., Gianna R., De Gregoriis E., Grandi G. Structural features of neutral protease from Bacillus subtilis deduced from model-building and limited proteolysis experiments. Eur. J. Biochem. 189:1990;221-227
57. Spivak-Kroizman T., Lemmon M.A., Dikic I., Ladbury J.E., Pinchsi D., Huang J., Jaye M., Crumley G., Schlessinger J., Lax I. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell. 79:1994;1015-1024
58. Springer B.A., Pantoliano M.W., Barbera F.A., Gunyuzlu P.L., Thompson L.D., Herblin W.F., Rosenfeld S.A., Book G.W. Identification and concerted function of two receptor binding surfaces on basic fibroblast growth factor required for mitogenesis. J. Biol. Chem. 269:1994;26879-26884
59. Stein C.A. Suramin a novel antineoplasic agent with multiple potential mechanisms of action. Cancer Res. 53:1993;2239-2248
60. Takano S., Gately S., Neville M.E., Herblin W.F., Gross J.L., Engelhard H., Perricone M., Eidsvoog K., Brem S. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res. 54:1994;2654-2660
61. Thomas K.A., Rios-Candelore M., Giménez-Gallego G., DiSalvo J., Bennett C., Rodkey J., Fitzpatrick S. Pure brain-derived acidic fibroblast growth factor is a potent angiogenic vascular endothelial cell mitogen with sequence homology to interleukin 1. Proc. Natl. Acd. Sci. USA. 82:1985;6409-6413
62. Thompson L.D., Pantoliano M.W., Springer B.A. Energetic characterization of the basic fibroblast growth factor heparin interaction identification of the heparin binding domain. Biochemistry. 33:1994;3831-3840
63. Voest E.E. Inhibitors of angiogenesis in a clinical perpective. Anti-Cancer Drugs. 7:1996;723-727
64. Volkin D.B., Tsai P.K., Dabora J.M., Gress J.O., Burke C.J., Linhardt R.J., Middaugh C.R. Physical stabilization of acidic fibroblast growth factor by polyanions. Arch. Biochem. Biophys. 300:1993;30-41
65. Wang Y., Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat. Med. 3:1997;887-893
66. Wüthrich K. NMR of Proteins and Nucleic Acids. 1986;J. Wiley & Sons, New York
67. Wüthrich K., Billeter M., Braun W. Polypeptide secondary structure determination by nuclear magnetic resonance observation of short proton-proton distances. J. Mol. Biol. 180:1984;715-740
68. Yayon A., Klagsbrun M. Autocrine transformation by chimeric signal peptide-basic fibroblast growth factor reversal by suramin. Proc. Natl Acad. Sci. USA. 87:1990;5346-5350
69. Yayon A., Klagsbrun M., Esko J.D., Leder P., Ornitz D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 64:1991;841-848
70. Zamai M., Parola A.H., Grandi M., Mongelli N., Caiolfa V.R. Antiangiogenic naptalene sulfonic distamycin-A derivatives tightly interact with basic fibroblast growth factor. Med. Chem. Res. 7:1997;36-44
71. Zazo M., Lozano R.M., Ortega S., Varela J., Díaz-Orejas R., Ramírez J.M., Giménez-Gallego G. High-level synthesis in Escherichia coli of shortened and full-length human acidic fibroblast growth factor and purification in a form stable in aqueous solutions. Gene. 113:1992;231-238